Natural products and chronic hepatitis C virus

被引:63
作者
Azzam, H. S.
Goertz, C.
Fritts, M.
Jonas, W. B.
机构
[1] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA
[2] Samueli Inst, Alexandria, VA USA
关键词
alternative treatments; chronic hepatitis C; Gomisin A; lactoferrin; natural products; oxymatrine; schisandra; TJ-108;
D O I
10.1111/j.1478-3231.2006.01408.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Chronic hepatitis C virus (HCV) infection is a significant public health problem, with a worldwide prevalence of approximately 170 million. The standard of care for chronic HCV, a combination of alpha-interferon (IFN) and ribavirin, is only 50% effective, has serious side effects, and can be prohibitively expensive for low-income countries with a high prevalence of HCV. Many patients use natural products, including those who are not eligible for IFN/ribavirin, cannot afford treatment, or fail to respond to IFN. Methods: Extensive literature searches were conducted in order to identify clinical trials and reviews of natural products used for treatment of chronic HCV. This review focuses on the composition, pharmacology and results of clinical trials of three natural products: Oxymatrine, TJ-108/schisandra/Gomisin A and lactoferrin. Results: Several laboratory and human studies have been performed to evalaute these alternative treatments, but many of these studies are small, uncontrolled and have other important design flaws. While they do offer some safety and efficacy data, none of these studies is conclusive. Conclusion: Further research is needed on the effectiveness of these natural products for treatment of chronic HCV, including their preparation and standardization.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 73 条
[1]
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[2]
[Anonymous], SCHIS MON
[3]
Aoki T, 1994, Arerugi, V43, P663
[4]
Natural history of compensated viral cirrhosis:: a prospective study on the incidence and hierarchy of major complications [J].
Benvegnù, L ;
Gios, M ;
Boccato, S ;
Alberti, A .
GUT, 2004, 53 (05) :744-749
[5]
Bernstein BJ, 2001, ONCOLOGY-NY, V15, P1267
[6]
BONIS PA, 2003, UPTODATE
[7]
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C:: A meta-analysis of individual patient data [J].
Cammà, C ;
Di Bona, D ;
Schepis, F ;
Heathcote, EJ ;
Zeuzem, S ;
Pockros, PJ ;
Marcellin, P ;
Balart, L ;
Alberti, A ;
Craxì, A .
HEPATOLOGY, 2004, 39 (02) :333-342
[8]
Chen XS, 2001, WORLD J GASTROENTERO, V7, P49
[9]
Chen Y, 2001, Zhonghua Gan Zang Bing Za Zhi, V9 Suppl, P12
[10]
Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force [J].
Chou, R ;
Clark, EC ;
Helfand, M .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (06) :465-479